Emergent Health Corp. Updates Shareholders Emerg
Post# of 94272
Posted On: 12/03/2013 8:32:42 AM
Emergent Health Corp. Updates Shareholders
Emergent Health Corp. (Pink Sheets:EMGE) (the "Company") is pleased to announce today there exists an agreement of sale executed on November 12, 2013 by its controlling shareholder for the Company control to be passed on to another controlling shareholder group, Clover Capital and Parcae Capital Corp. Per the agreement, it is the intention of the newly acquiring group, if and when the closing occurs, for the Company to file audited statements and file with the Securities and Exchange Commission to become a fully compliant reporting entity and to effect an upgrade of its trading status above the current OTC Market stage.
It is understood by the Company the intent of the new controlling group and its management team is to expand the market for the Company's patented and patent pending products above and beyond its current network marketing division. The Company products include those oriented towards stem cell nutrition, telomere support, weight loss and nutritional support for debilitating illnesses among other product innovations.
The Company has spent considerable time and resources to develop a portfolio of patented and patent pending nutritionally designed products which are being accepted in the market place. The Company believes it is now ready to go to the next level of acceptance. Upon the conclusion of this pending transaction and with new products in our pipeline soon to be released, the Company believes it has good reason to be optimistic about its future.
The Company would like to thank its shareholders for their patience through the developmental stage of the Company.
About Emergent Health Corp.
Emergent Health Corp., a diversified biotechnology firm, is focused on the health and wellness industry. With patented and patent pending nutritionally designed products, Emergent believes it is positioning itself as a leader in the field of Regenerative Medicine as defined by the National Institute of Health.
This press release contains certain "forward-looking" statements, defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are estimates reflecting the company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors, factors that could cause actual results to differ materially from those estimated by the company.
This press release is provided for information purposes only and is not intended to constitute an offer to sell or a solicitation of an offer to buy securities.
CONTACT: Emergent Health Corp.
484-518-9000
Emergent Health Corp. (Pink Sheets:EMGE) (the "Company") is pleased to announce today there exists an agreement of sale executed on November 12, 2013 by its controlling shareholder for the Company control to be passed on to another controlling shareholder group, Clover Capital and Parcae Capital Corp. Per the agreement, it is the intention of the newly acquiring group, if and when the closing occurs, for the Company to file audited statements and file with the Securities and Exchange Commission to become a fully compliant reporting entity and to effect an upgrade of its trading status above the current OTC Market stage.
It is understood by the Company the intent of the new controlling group and its management team is to expand the market for the Company's patented and patent pending products above and beyond its current network marketing division. The Company products include those oriented towards stem cell nutrition, telomere support, weight loss and nutritional support for debilitating illnesses among other product innovations.
The Company has spent considerable time and resources to develop a portfolio of patented and patent pending nutritionally designed products which are being accepted in the market place. The Company believes it is now ready to go to the next level of acceptance. Upon the conclusion of this pending transaction and with new products in our pipeline soon to be released, the Company believes it has good reason to be optimistic about its future.
The Company would like to thank its shareholders for their patience through the developmental stage of the Company.
About Emergent Health Corp.
Emergent Health Corp., a diversified biotechnology firm, is focused on the health and wellness industry. With patented and patent pending nutritionally designed products, Emergent believes it is positioning itself as a leader in the field of Regenerative Medicine as defined by the National Institute of Health.
This press release contains certain "forward-looking" statements, defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are estimates reflecting the company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors, factors that could cause actual results to differ materially from those estimated by the company.
This press release is provided for information purposes only and is not intended to constitute an offer to sell or a solicitation of an offer to buy securities.
CONTACT: Emergent Health Corp.
484-518-9000
(0)
(0)